Medical Deferoxamine Mesylate Market Report 2026

Medical Deferoxamine Mesylate Market Overview

• Medical Deferoxamine Mesylate market size has reached to $1.28 billion in 2025 • Expected to grow to $1.91 billion in 2030 at a compound annual growth rate (CAGR) of 8.3% • Growth Driver: Increasing Prevalence Of Iron Overload Disorders Fueling The Growth Of The Market Due To Rising Demand For Effective Iron Removal Therapies • Market Trend: Expanding Access To Iron Overload Treatments Through Generic Drug Launches • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Medical Deferoxamine Mesylate Market?

Medical deferoxamine mesylate is a drug that helps remove extra iron from the body. It is mainly given to people who have dangerously high iron levels, due to repeated blood transfusions. The medicine attaches to the surplus iron, allowing the body to safely get rid of it through urine or bile. The main product types of medical deferoxamine mesylate are injectable, oral, and topical formulations. Injectable products are substances or medications administered into the body using a needle and syringe. Routes of administration include subcutaneous, intramuscular, and intravenous methods. These are distributed through various distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Key applications include the treatment of iron overload disorders, aluminum toxicity, acute iron poisoning, and others. It is primarily used for various end users such as hospitals and clinics.

What Is The Medical Deferoxamine Mesylate Market Growth Forecast?

The medical deferoxamine mesylate market size is expected to see strong growth in the next few years. It will grow to $1.91 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing development of alternative chelation drugs, rising focus on patient-friendly formulations, expansion of rare disease treatment programs, growing investments in specialty pharmaceuticals, increasing awareness of iron toxicity management. Major trends in the forecast period include increasing demand for iron chelation therapies, rising use of injectable deferoxamine formulations, expansion of hospital-based iron overload treatment, growing focus on chronic transfusion management, enhanced emphasis on treatment compliance.

Global Medical Deferoxamine Mesylate Market Segmentation

1) By Product Type: Injectable, Parenteral Formulations 2) By Route Of Administration: Subcutaneous, Intramuscular, Intravenous? 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others Distribution Channel 4) By Application: Iron Overload Disorders, Aluminum Toxicity, Acute Iron Poisoning, Other Applications 5) By End-User: Hospitals, Clinics Subsegments: 1) By Injectable: Intramuscular (IM), Intravenous (IV), Subcutaneous (SC) 2) By Parenteral Formulations: Intravenous, Subcutaneous, Intramuscular

What Is The Driver Of The Medical Deferoxamine Mesylate Market?

The increasing prevalence of iron overload disorders is expected to propel the growth of the medical deferoxamine mesylate market going forward. Iron overload disorders refer to medical conditions in which excess iron builds up in the body, due to genetic factors, frequent blood transfusions, or certain chronic diseases. The widespread use of long-term blood transfusions to manage chronic hemoglobinopathies coupled with improved patient survival has expanded the at-risk population and driven an increase in iron overload disorders. Medical deferoxamine mesylate is useful for treating iron overload by removing excess iron from the body, preventing organ damage, and helping patients with conditions such as thalassemia and hemochromatosis. For instance, in March 2023, according to the Electronic Journal of General Medicine, a UK-based medical journal, reported that 10.73% of patients (1,085) have alpha-thalassemia, 2.24% (227) have beta-thalassemia, and 0.29% (29) carry both mutations. Therefore, the increasing prevalence of iron overload disorders is driving the growth of the medical deferoxamine mesylate industry.

Key Players In The Global Medical Deferoxamine Mesylate Market

Major companies operating in the medical deferoxamine mesylate market are Novartis AG, Merck KGaA, Teva Pharmaceutical Industries Inc., Intas Pharmaceuticals Ltd., Fresenius Kabi AG, Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., Hospira Inc., Manus Aktteva Biopharma LLP, Merit Pharmaceuticals Inc., Aurobindo Pharma Ltd., Cipla Limited, Cadila Healthcare Ltd., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Pharmacosmos A/S, American Regent Inc., Ferring Pharmaceuticals, Sandoz Inc., Emcure Pharmaceuticals Ltd., Akorn Incorporated, Dr. Reddy’s Laboratories Ltd.

Global Medical Deferoxamine Mesylate Market Trends and Insights

Major companies operating in the medical deferoxamine mesylate market are focusing on developing generic version of drugs, to expand patient access, reduce treatment costs, and strengthen their competitive position in the global market. A generic drug is a cheaper alternative to a brand-name medicine, containing the same active ingredients and delivering the same therapeutic effects once the original patent ends. For instance, in January 2023, Pharmascience Inc., a Canada-based pharmaceutical company, launched PRpms-DEFERASIROX (TYPE J), a lower-cost alternative to Jadenu, to treat chronic iron overload in both children and adults with anemia or thalassemia, offering the same safety and effectiveness in 90 mg and 360 mg tablets.

What Are Latest Mergers And Acquisitions In The Medical Deferoxamine Mesylate Market?

In September 2024, Mitem Pharma, a France-based pharmaceutical company, acquired the worldwide rights to DESFERAL (deferoxamine mesylate) from Novartis AG for an undisclosed amount. Through this acquisition, it aims to expand its presence in the iron chelation therapy sector and enhance its portfolio with a well-established treatment for managing iron overload disorders. Novartis AG is a Switzerland-based pharmaceutical company specializes in manufacturing therapeutic drugs for rare diseases.

Regional Outlook

North America was the largest region in the medical deferoxamine mesylate market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Medical Deferoxamine Mesylate Market?

The medical deferoxamine mesylate market consists of sales of infusion pumps, syringes, and generic version of drug. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.